Skip to content
CancerIndex

Country

United States

Cancer incidence and mortality for United States as published by the source registry: per site group, per year and sex, with age-standardized rates where the source provides them. Population statistics describe groups, never individuals.

ISO 3166-1
USA · US
WHO region
WHO Region of the Americas
Population
not seeded — CancerIndex shows only rates and counts published by the source
Years covered
1999–2024
Cancer entities
36
Estimate types
observed

Summary

2016 · Female · all ages

Totals across all cancer sites are shown only when the source publishes an all-sites row. Otherwise the per-site figures below stand on their own; CancerIndex never sums site groups (definitions overlap between sources).

  • Deathshighest site group:Malignant Lung Neoplasm68,094countcdc-uscsProvenance
    Source
    U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
    Dataset
    U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
    Version
    USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
    Retrieved
    Sep 8, 2026
    Layer
    normalized (units and labels harmonized; values unchanged)
    Evidence
    registry
    License
    US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
    Run
    ING-CDCUSCS-20260908-000001
    Open at source     Observed28 site groups
  • New caseshighest site group:Malignant Breast Neoplasm251,791countcdc-uscsProvenance
    Source
    U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
    Dataset
    U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
    Version
    USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
    Retrieved
    Sep 8, 2026
    Layer
    normalized (units and labels harmonized; values unchanged)
    Evidence
    registry
    License
    US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
    Run
    ING-CDCUSCS-20260908-000001
    Open at source     Observed29 site groups
  • Mortality rate (age-standardized)highest site group:Malignant Lung Neoplasm32.5per 100,000cdc-uscsProvenance
    Source
    U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
    Dataset
    U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
    Version
    USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
    Retrieved
    Sep 8, 2026
    Layer
    normalized (units and labels harmonized; values unchanged)
    Evidence
    registry
    License
    US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
    Run
    ING-CDCUSCS-20260908-000001
    Open at source     Observed28 site groups
  • Incidence rate (age-standardized)highest site group:Malignant Breast Neoplasm128.5per 100,000cdc-uscsProvenance
    Source
    U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
    Dataset
    U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
    Version
    USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
    Retrieved
    Sep 8, 2026
    Layer
    normalized (units and labels harmonized; values unchanged)
    Evidence
    registry
    License
    US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
    Run
    ING-CDCUSCS-20260908-000001
    Open at source     Observed29 site groups

No all-sites total in source for this scope — per-site figures below; no national total is computed.

Top cancers

By deaths

2016 · Female · all ages · 28 site groups

#CancerDeaths (count)95% CITypeRank in scopeSite definitionSource
1Malignant Lung NeoplasmCancer68,094—observed#1 of 28USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349)cdc-uscsObserved
2Malignant Breast NeoplasmCancer Family41,487—observed#2 of 28USCS "Female Breast" (ICD-10 C50; ICD-O-3 C500-C509)cdc-uscsObserved
3Malignant Pancreatic NeoplasmCancer20,858—observed#3 of 28USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259)cdc-uscsObserved
4Malignant Colon NeoplasmCancer20,315—observed#4 of 28USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260)cdc-uscsObserved
5Malignant Ovarian NeoplasmCancer14,223—observed#5 of 28USCS "Ovary" (ICD-10 C56; ICD-O-3 C569)cdc-uscsObserved
6LeukemiaCancer Family9,927—observed#6 of 28USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode)cdc-uscsObserved
7Non-Hodgkin LymphomaHematologic Malignancy8,968—observed#7 of 28USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood))cdc-uscsObserved
8Malignant Liver NeoplasmCancer8,726—observed#8 of 28USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221)cdc-uscsObserved
9Malignant Central Nervous System NeoplasmCancer7,324—observed#9 of 28USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729)cdc-uscsObserved
10Multiple MyelomaHematologic Malignancy5,532—observed#10 of 28USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734)cdc-uscsObserved
11Malignant Uterine Corpus NeoplasmCancer5,410—observed#11 of 28USCS "Corpus" (ICD-10 C54; ICD-O-3 C540-C549)cdc-uscsObserved
12Malignant Kidney NeoplasmCancer4,846—observed#12 of 28USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659)cdc-uscsObserved
13Malignant Bladder NeoplasmCancer4,705—observed#13 of 28USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679)cdc-uscsObserved
14Malignant Gastric NeoplasmCancer4,588—observed#14 of 28USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169)cdc-uscsObserved
15Malignant Rectal NeoplasmCancer4,329—observed#15 of 28USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209)cdc-uscsObserved
16Malignant Cervical NeoplasmCancer4,188—observed#16 of 28USCS "Cervix" (ICD-10 C53; ICD-O-3 C530-C539)cdc-uscsObserved
17Malignant Esophageal NeoplasmCancer3,142—observed#17 of 28USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159)cdc-uscsObserved
18Cutaneous MelanomaCancer2,763—observed#18 of 28USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790)cdc-uscsObserved
19Malignant Vulvar NeoplasmCancer1,221—observed#19 of 28USCS "Vulva" (ICD-10 C51; ICD-O-3 C510-C519)cdc-uscsObserved
20Malignant Thyroid Gland NeoplasmCancer1,116—observed#20 of 28USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739)cdc-uscsObserved
21Malignant Laryngeal NeoplasmCancer818—observed#21 of 28USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329)cdc-uscsObserved
22Malignant Anal NeoplasmCancer703—observed#22 of 28USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218)cdc-uscsObserved
23Malignant MesotheliomaCancer Family536—observed#23 of 28USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site))cdc-uscsObserved
24Hodgkin LymphomaHematologic Malignancy421—observed#24 of 28USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal))cdc-uscsObserved
25Malignant Vaginal NeoplasmCancer386—observed#25 of 28USCS "Vagina" (ICD-10 C52; ICD-O-3 C529)cdc-uscsObserved
26Malignant Salivary Gland NeoplasmCancer374—observed#26 of 28USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089)cdc-uscsObserved
27Malignant Nasopharyngeal NeoplasmCancer216—observed#27 of 28USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119)cdc-uscsObserved
28Malignant Hypopharyngeal NeoplasmCancer81—observed#28 of 28USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139)cdc-uscsObserved
cdc-uscsProvenance
Source
U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
Dataset
U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
Version
USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
registry
License
US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
Run
ING-CDCUSCS-20260908-000001
Open at source Rank from snapshot geo=USA|sex=female|age=all|year=2016|level=top · full ranking and "Why this rank?"High confidencetrend ↓

Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)

Top cancers

By new cases

2016 · Female · all ages · 29 site groups

#CancerNew cases (count)95% CITypeRank in scopeSite definitionSource
1Malignant Breast NeoplasmCancer Family251,791—observed#1 of 29USCS "Female Breast" (ICD-10 C50; ICD-O-3 C500-C509)cdc-uscsObserved
2Malignant Lung NeoplasmCancer108,889—observed#2 of 29USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349)cdc-uscsObserved
3Malignant Uterine Corpus NeoplasmCancer55,942—observed#3 of 29USCS "Corpus" (ICD-10 C54; ICD-O-3 C540-C549)cdc-uscsObserved
4Malignant Colon NeoplasmCancer52,038—observed#4 of 29USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260)cdc-uscsObserved
5Malignant Thyroid Gland NeoplasmCancer36,542—observed#5 of 29USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739)cdc-uscsObserved
6Cutaneous MelanomaCancer34,808—observed#6 of 29USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790)cdc-uscsObserved
7Non-Hodgkin LymphomaHematologic Malignancy33,072—observed#7 of 29USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood))cdc-uscsObserved
8Malignant Pancreatic NeoplasmCancer24,634—observed#8 of 29USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259)cdc-uscsObserved
9Malignant Kidney NeoplasmCancer24,142—observed#9 of 29USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659)cdc-uscsObserved
10LeukemiaCancer Family22,636—observed#10 of 29USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode)cdc-uscsObserved
11Malignant Ovarian NeoplasmCancer21,388—observed#11 of 29USCS "Ovary" (ICD-10 C56; ICD-O-3 C569)cdc-uscsObserved
12Malignant Bladder NeoplasmCancer18,408—observed#12 of 29USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679)cdc-uscsObserved
13Malignant Rectal NeoplasmCancer17,490—observed#13 of 29USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209)cdc-uscsObserved
14Malignant Cervical NeoplasmCancer13,409—observed#14 of 29USCS "Cervix" (ICD-10 C53; ICD-O-3 C530-C539)cdc-uscsObserved
15Multiple MyelomaHematologic Malignancy12,490—observed#15 of 29USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734)cdc-uscsObserved
16Malignant Central Nervous System NeoplasmCancer10,284—observed#16 of 29USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729)cdc-uscsObserved
17Malignant Liver NeoplasmCancer10,045—observed#17 of 29USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221)cdc-uscsObserved
18Malignant Gastric NeoplasmCancer9,634—observed#18 of 29USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169)cdc-uscsObserved
19Malignant Vulvar NeoplasmCancer5,358—observed#19 of 29USCS "Vulva" (ICD-10 C51; ICD-O-3 C510-C519)cdc-uscsObserved
20Malignant Anal NeoplasmCancer5,090—observed#20 of 29USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218)cdc-uscsObserved
21Hodgkin LymphomaHematologic Malignancy3,937—observed#21 of 29USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal))cdc-uscsObserved
22Malignant Esophageal NeoplasmCancer3,784—observed#22 of 29USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159)cdc-uscsObserved
23Malignant Laryngeal NeoplasmCancer2,590—observed#23 of 29USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329)cdc-uscsObserved
24Malignant Salivary Gland NeoplasmCancer1,974—observed#24 of 29USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089)cdc-uscsObserved
25Malignant Vaginal NeoplasmCancer1,345—observed#25 of 29USCS "Vagina" (ICD-10 C52; ICD-O-3 C529)cdc-uscsObserved
26Malignant MesotheliomaCancer Family800—observed#26 of 29USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site))cdc-uscsObserved
27Malignant Nasopharyngeal NeoplasmCancer545—observed#27 of 29USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119)cdc-uscsObserved
28Malignant Hypopharyngeal NeoplasmCancer481—observed#28 of 29USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139)cdc-uscsObserved
29Kaposi SarcomaCancer123—observed#29 of 29USCS "Kaposi Sarcoma" (ICD-10 C46; ICD-O-3 histology 9140 (any site))cdc-uscsObserved
cdc-uscsProvenance
Source
U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
Dataset
U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
Version
USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
registry
License
US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
Run
ING-CDCUSCS-20260908-000001
Open at source Rank from snapshot geo=USA|sex=female|age=all|year=2016|level=top · full ranking and "Why this rank?"High confidencetrend ↓

Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)

Top cancers

By mortality rate (age-standardized)

2016 · Female · all ages · 28 site groups · 2000 U.S. standard population (19 age groups)

#CancerMortality rate (age-standardized) (per 100,000)95% CITypeRank in scopeSite definitionSource
1Malignant Lung NeoplasmCancer32.532.3–32.8observed#1 of 28USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349)cdc-uscsObserved
2Malignant Breast NeoplasmCancer Family20.320.1–20.5observed#2 of 28USCS "Female Breast" (ICD-10 C50; ICD-O-3 C500-C509)cdc-uscsObserved
3Malignant Pancreatic NeoplasmCancer9.99.8–10observed#3 of 28USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259)cdc-uscsObserved
4Malignant Colon NeoplasmCancer9.79.6–9.8observed#4 of 28USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260)cdc-uscsObserved
5Malignant Ovarian NeoplasmCancer6.96.8–7observed#5 of 28USCS "Ovary" (ICD-10 C56; ICD-O-3 C569)cdc-uscsObserved
6LeukemiaCancer Family4.94.8–5observed#6 of 28USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode)cdc-uscsObserved
7Non-Hodgkin LymphomaHematologic Malignancy4.34.2–4.4observed#7 of 28USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood))cdc-uscsObserved
8Malignant Liver NeoplasmCancer4.24.1–4.2observed#8 of 28USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221)cdc-uscsObserved
9Malignant Central Nervous System NeoplasmCancer3.73.6–3.8observed#9 of 28USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729)cdc-uscsObserved
10Malignant Uterine Corpus NeoplasmCancer2.62.5–2.6observed#10 of 28USCS "Corpus" (ICD-10 C54; ICD-O-3 C540-C549)cdc-uscsObserved
11Multiple MyelomaHematologic Malignancy2.62.6–2.7observed#10 of 28USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734)cdc-uscsObserved
12Malignant Cervical NeoplasmCancer2.32.2–2.3observed#12 of 28USCS "Cervix" (ICD-10 C53; ICD-O-3 C530-C539)cdc-uscsObserved
13Malignant Kidney NeoplasmCancer2.32.2–2.4observed#12 of 28USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659)cdc-uscsObserved
14Malignant Bladder NeoplasmCancer2.22.1–2.3observed#14 of 28USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679)cdc-uscsObserved
15Malignant Gastric NeoplasmCancer2.22.2–2.3observed#14 of 28USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169)cdc-uscsObserved
16Malignant Rectal NeoplasmCancer2.12–2.2observed#16 of 28USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209)cdc-uscsObserved
17Malignant Esophageal NeoplasmCancer1.51.4–1.5observed#17 of 28USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159)cdc-uscsObserved
18Cutaneous MelanomaCancer1.41.3–1.4observed#18 of 28USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790)cdc-uscsObserved
19Malignant Vulvar NeoplasmCancer0.60.5–0.6observed#19 of 28USCS "Vulva" (ICD-10 C51; ICD-O-3 C510-C519)cdc-uscsObserved
20Malignant Thyroid Gland NeoplasmCancer0.50.5–0.6observed#20 of 28USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739)cdc-uscsObserved
21Malignant Laryngeal NeoplasmCancer0.40.4–0.4observed#21 of 28USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329)cdc-uscsObserved
22Malignant Anal NeoplasmCancer0.30.3–0.4observed#22 of 28USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218)cdc-uscsObserved
23Malignant MesotheliomaCancer Family0.30.2–0.3observed#22 of 28USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site))cdc-uscsObserved
24Hodgkin LymphomaHematologic Malignancy0.20.2–0.2observed#24 of 28USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal))cdc-uscsObserved
25Malignant Salivary Gland NeoplasmCancer0.20.2–0.2observed#24 of 28USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089)cdc-uscsObserved
26Malignant Vaginal NeoplasmCancer0.20.2–0.2observed#24 of 28USCS "Vagina" (ICD-10 C52; ICD-O-3 C529)cdc-uscsObserved
27Malignant Nasopharyngeal NeoplasmCancer0.10.1–0.1observed#27 of 28USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119)cdc-uscsObserved
28Malignant Hypopharyngeal NeoplasmCancer00–0observed#28 of 28USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139)cdc-uscsObserved
cdc-uscsProvenance
Source
U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
Dataset
U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
Version
USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
registry
License
US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
Run
ING-CDCUSCS-20260908-000001
Open at source Rank from snapshot geo=USA|sex=female|age=all|year=2016|level=top · full ranking and "Why this rank?"High confidencetrend ↓

Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)

Top cancers

By incidence rate (age-standardized)

2016 · Female · all ages · 29 site groups · 2000 U.S. standard population (19 age groups)

#CancerIncidence rate (age-standardized) (per 100,000)95% CITypeRank in scopeSite definitionSource
1Malignant Breast NeoplasmCancer Family128.5128–129observed#1 of 29USCS "Female Breast" (ICD-10 C50; ICD-O-3 C500-C509)cdc-uscsObserved
2Malignant Lung NeoplasmCancer52.151.8–52.5observed#2 of 29USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349)cdc-uscsObserved
3Malignant Uterine Corpus NeoplasmCancer27.126.9–27.3observed#3 of 29USCS "Corpus" (ICD-10 C54; ICD-O-3 C540-C549)cdc-uscsObserved
4Malignant Colon NeoplasmCancer25.825.6–26.1observed#4 of 29USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260)cdc-uscsObserved
5Malignant Thyroid Gland NeoplasmCancer21.321.1–21.5observed#5 of 29USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739)cdc-uscsObserved
6Cutaneous MelanomaCancer18.418.2–18.6observed#6 of 29USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790)cdc-uscsObserved
7Non-Hodgkin LymphomaHematologic Malignancy16.516.3–16.7observed#7 of 29USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood))cdc-uscsObserved
8Malignant Kidney NeoplasmCancer12.112–12.3observed#8 of 29USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659)cdc-uscsObserved
9Malignant Pancreatic NeoplasmCancer11.811.7–12observed#9 of 29USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259)cdc-uscsObserved
10LeukemiaCancer Family11.711.5–11.8observed#10 of 29USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode)cdc-uscsObserved
11Malignant Ovarian NeoplasmCancer10.910.8–11.1observed#11 of 29USCS "Ovary" (ICD-10 C56; ICD-O-3 C569)cdc-uscsObserved
12Malignant Rectal NeoplasmCancer8.98.7–9observed#12 of 29USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209)cdc-uscsObserved
13Malignant Bladder NeoplasmCancer8.88.7–9observed#13 of 29USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679)cdc-uscsObserved
14Malignant Cervical NeoplasmCancer7.97.8–8.1observed#14 of 29USCS "Cervix" (ICD-10 C53; ICD-O-3 C530-C539)cdc-uscsObserved
15Multiple MyelomaHematologic Malignancy6.15.9–6.2observed#15 of 29USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734)cdc-uscsObserved
16Malignant Central Nervous System NeoplasmCancer5.65.4–5.7observed#16 of 29USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729)cdc-uscsObserved
17Malignant Gastric NeoplasmCancer4.84.7–4.9observed#17 of 29USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169)cdc-uscsObserved
18Malignant Liver NeoplasmCancer4.84.7–4.9observed#17 of 29USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221)cdc-uscsObserved
19Malignant Vulvar NeoplasmCancer2.72.6–2.7observed#19 of 29USCS "Vulva" (ICD-10 C51; ICD-O-3 C510-C519)cdc-uscsObserved
20Malignant Anal NeoplasmCancer2.52.4–2.5observed#20 of 29USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218)cdc-uscsObserved
21Hodgkin LymphomaHematologic Malignancy2.42.3–2.4observed#21 of 29USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal))cdc-uscsObserved
22Malignant Esophageal NeoplasmCancer1.81.7–1.9observed#22 of 29USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159)cdc-uscsObserved
23Malignant Laryngeal NeoplasmCancer1.21.2–1.3observed#23 of 29USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329)cdc-uscsObserved
24Malignant Salivary Gland NeoplasmCancer11–1.1observed#24 of 29USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089)cdc-uscsObserved
25Malignant Vaginal NeoplasmCancer0.70.6–0.7observed#25 of 29USCS "Vagina" (ICD-10 C52; ICD-O-3 C529)cdc-uscsObserved
26Malignant MesotheliomaCancer Family0.40.4–0.4observed#26 of 29USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site))cdc-uscsObserved
27Malignant Nasopharyngeal NeoplasmCancer0.30.3–0.3observed#27 of 29USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119)cdc-uscsObserved
28Malignant Hypopharyngeal NeoplasmCancer0.20.2–0.3observed#28 of 29USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139)cdc-uscsObserved
29Kaposi SarcomaCancer0.10.1–0.1observed#29 of 29USCS "Kaposi Sarcoma" (ICD-10 C46; ICD-O-3 histology 9140 (any site))cdc-uscsObserved
cdc-uscsProvenance
Source
U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
Dataset
U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
Version
USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
registry
License
US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
Run
ING-CDCUSCS-20260908-000001
Open at source Rank from snapshot geo=USA|sex=female|age=all|year=2016|level=top · full ranking and "Why this rank?"High confidencetrend ↓

Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)

Trend

Mortality rate (age-standardized) — top 8 cancers, all years

Top cancers of 2016 (Female) traced over every year published for United States. Dashed lines mark estimated or projected values; the y axis starts at zero.

Mortality rate (age-standardized) by year for the top 8 cancers in United States09182735.944.9per 100,0001999200020052010201520202024Malignant Lung Neoplasm — 1999: 40.1Malignant Lung Neoplasm — 2000: 41.1Malignant Lung Neoplasm — 2001: 41Malignant Lung Neoplasm — 2002: 41.6Malignant Lung Neoplasm — 2003: 41.3Malignant Lung Neoplasm — 2004: 41Malignant Lung Neoplasm — 2005: 40.7Malignant Lung Neoplasm — 2006: 40.3Malignant Lung Neoplasm — 2007: 40.1Malignant Lung Neoplasm — 2008: 39.1Malignant Lung Neoplasm — 2009: 38.6Malignant Lung Neoplasm — 2010: 38Malignant Lung Neoplasm — 2011: 37.1Malignant Lung Neoplasm — 2012: 36.7Malignant Lung Neoplasm — 2013: 35.8Malignant Lung Neoplasm — 2014: 35.2Malignant Lung Neoplasm — 2015: 34.1Malignant Lung Neoplasm — 2016: 32.5Malignant Lung Neoplasm — 2017: 31.3Malignant Lung Neoplasm — 2018: 29.3Malignant Lung Neoplasm — 2018: 29.3Malignant Lung Neoplasm — 2019: 28.2Malignant Lung Neoplasm — 2019: 28.1Malignant Lung Neoplasm — 2020: 27Malignant Lung Neoplasm — 2020: 27.6Malignant Lung Neoplasm — 2021: 27.3Malignant Lung Neoplasm — 2021: 27Malignant Lung Neoplasm — 2022: 26Malignant Lung Neoplasm — 2022: 26.1Malignant Lung Neoplasm — 2023: 25.6Malignant Lung Neoplasm — 2023: 25.8Malignant Lung Neoplasm — 2024: 24.4Malignant Lung Neoplasm — 2024: 24.6Malignant Breast Neoplasm — 1999: 26.6Malignant Breast Neoplasm — 2000: 26.6Malignant Breast Neoplasm — 2001: 26Malignant Breast Neoplasm — 2002: 25.6Malignant Breast Neoplasm — 2003: 25.3Malignant Breast Neoplasm — 2004: 24.5Malignant Breast Neoplasm — 2005: 24.1Malignant Breast Neoplasm — 2006: 23.6Malignant Breast Neoplasm — 2007: 23Malignant Breast Neoplasm — 2008: 22.6Malignant Breast Neoplasm — 2009: 22.2Malignant Breast Neoplasm — 2010: 21.9Malignant Breast Neoplasm — 2011: 21.6Malignant Breast Neoplasm — 2012: 21.4Malignant Breast Neoplasm — 2013: 20.9Malignant Breast Neoplasm — 2014: 20.8Malignant Breast Neoplasm — 2015: 20.6Malignant Breast Neoplasm — 2016: 20.3Malignant Breast Neoplasm — 2017: 20.2Malignant Breast Neoplasm — 2018: 19.7Malignant Breast Neoplasm — 2018: 19.8Malignant Breast Neoplasm — 2019: 19.4Malignant Breast Neoplasm — 2019: 19.4Malignant Breast Neoplasm — 2020: 19.1Malignant Breast Neoplasm — 2020: 19.5Malignant Breast Neoplasm — 2021: 19.3Malignant Breast Neoplasm — 2021: 19.4Malignant Breast Neoplasm — 2022: 18.8Malignant Breast Neoplasm — 2022: 18.9Malignant Breast Neoplasm — 2023: 18.7Malignant Breast Neoplasm — 2023: 18.5Malignant Breast Neoplasm — 2024: 18.7Malignant Breast Neoplasm — 2024: 18.7Malignant Pancreatic Neoplasm — 1999: 9.3Malignant Pancreatic Neoplasm — 2000: 9.3Malignant Pancreatic Neoplasm — 2001: 9.3Malignant Pancreatic Neoplasm — 2002: 9.2Malignant Pancreatic Neoplasm — 2003: 9.3Malignant Pancreatic Neoplasm — 2004: 9.3Malignant Pancreatic Neoplasm — 2005: 9.5Malignant Pancreatic Neoplasm — 2006: 9.6Malignant Pancreatic Neoplasm — 2007: 9.5Malignant Pancreatic Neoplasm — 2008: 9.7Malignant Pancreatic Neoplasm — 2009: 9.5Malignant Pancreatic Neoplasm — 2010: 9.6Malignant Pancreatic Neoplasm — 2011: 9.6Malignant Pancreatic Neoplasm — 2012: 9.7Malignant Pancreatic Neoplasm — 2013: 9.6Malignant Pancreatic Neoplasm — 2014: 9.6Malignant Pancreatic Neoplasm — 2015: 9.8Malignant Pancreatic Neoplasm — 2016: 9.9Malignant Pancreatic Neoplasm — 2017: 9.8Malignant Pancreatic Neoplasm — 2018: 9.6Malignant Pancreatic Neoplasm — 2018: 9.7Malignant Pancreatic Neoplasm — 2019: 9.6Malignant Pancreatic Neoplasm — 2019: 9.6Malignant Pancreatic Neoplasm — 2020: 9.6Malignant Pancreatic Neoplasm — 2020: 9.9Malignant Pancreatic Neoplasm — 2021: 9.9Malignant Pancreatic Neoplasm — 2021: 10Malignant Pancreatic Neoplasm — 2022: 9.8Malignant Pancreatic Neoplasm — 2022: 9.7Malignant Pancreatic Neoplasm — 2023: 9.9Malignant Pancreatic Neoplasm — 2023: 9.8Malignant Pancreatic Neoplasm — 2024: 9.9Malignant Pancreatic Neoplasm — 2024: 10Malignant Colon Neoplasm — 1999: 15.4Malignant Colon Neoplasm — 2000: 15.2Malignant Colon Neoplasm — 2001: 14.8Malignant Colon Neoplasm — 2002: 14.3Malignant Colon Neoplasm — 2003: 14Malignant Colon Neoplasm — 2004: 13.1Malignant Colon Neoplasm — 2005: 12.6Malignant Colon Neoplasm — 2006: 12.5Malignant Colon Neoplasm — 2007: 12.2Malignant Colon Neoplasm — 2008: 11.8Malignant Colon Neoplasm — 2009: 11.1Malignant Colon Neoplasm — 2010: 10.8Malignant Colon Neoplasm — 2011: 10.7Malignant Colon Neoplasm — 2012: 10.4Malignant Colon Neoplasm — 2013: 10.2Malignant Colon Neoplasm — 2014: 10Malignant Colon Neoplasm — 2015: 10Malignant Colon Neoplasm — 2016: 9.7Malignant Colon Neoplasm — 2017: 9.5Malignant Colon Neoplasm — 2018: 9Malignant Colon Neoplasm — 2018: 8.9Malignant Colon Neoplasm — 2019: 8.7Malignant Colon Neoplasm — 2019: 8.7Malignant Colon Neoplasm — 2020: 8.4Malignant Colon Neoplasm — 2020: 8.7Malignant Colon Neoplasm — 2021: 8.7Malignant Colon Neoplasm — 2021: 8.7Malignant Colon Neoplasm — 2022: 8.5Malignant Colon Neoplasm — 2022: 8.3Malignant Colon Neoplasm — 2023: 8.4Malignant Colon Neoplasm — 2023: 8.4Malignant Colon Neoplasm — 2024: 8.3Malignant Colon Neoplasm — 2024: 8.2Malignant Ovarian Neoplasm — 1999: 8.8Malignant Ovarian Neoplasm — 2000: 8.9Malignant Ovarian Neoplasm — 2001: 9Malignant Ovarian Neoplasm — 2002: 9Malignant Ovarian Neoplasm — 2003: 8.9Malignant Ovarian Neoplasm — 2004: 8.8Malignant Ovarian Neoplasm — 2005: 8.7Malignant Ovarian Neoplasm — 2006: 8.6Malignant Ovarian Neoplasm — 2007: 8.3Malignant Ovarian Neoplasm — 2008: 8Malignant Ovarian Neoplasm — 2009: 7.9Malignant Ovarian Neoplasm — 2010: 7.8Malignant Ovarian Neoplasm — 2011: 7.6Malignant Ovarian Neoplasm — 2012: 7.4Malignant Ovarian Neoplasm — 2013: 7.3Malignant Ovarian Neoplasm — 2014: 7.1Malignant Ovarian Neoplasm — 2015: 6.8Malignant Ovarian Neoplasm — 2016: 6.9Malignant Ovarian Neoplasm — 2017: 6.7Malignant Ovarian Neoplasm — 2018: 6.3Malignant Ovarian Neoplasm — 2018: 6.3Malignant Ovarian Neoplasm — 2019: 6Malignant Ovarian Neoplasm — 2019: 6Malignant Ovarian Neoplasm — 2020: 6.1Malignant Ovarian Neoplasm — 2020: 5.9Malignant Ovarian Neoplasm — 2021: 6Malignant Ovarian Neoplasm — 2021: 6Malignant Ovarian Neoplasm — 2022: 5.8Malignant Ovarian Neoplasm — 2022: 5.8Malignant Ovarian Neoplasm — 2023: 5.5Malignant Ovarian Neoplasm — 2023: 5.5Malignant Ovarian Neoplasm — 2024: 5.3Malignant Ovarian Neoplasm — 2024: 5.3Malignant Liver Neoplasm — 1999: 2.9Malignant Liver Neoplasm — 2000: 2.9Malignant Liver Neoplasm — 2001: 3Malignant Liver Neoplasm — 2002: 3Malignant Liver Neoplasm — 2003: 3.1Malignant Liver Neoplasm — 2004: 3.2Malignant Liver Neoplasm — 2005: 3.2Malignant Liver Neoplasm — 2006: 3.3Malignant Liver Neoplasm — 2007: 3.3Malignant Liver Neoplasm — 2008: 3.3Malignant Liver Neoplasm — 2009: 3.4Malignant Liver Neoplasm — 2010: 3.5Malignant Liver Neoplasm — 2011: 3.7Malignant Liver Neoplasm — 2012: 3.8Malignant Liver Neoplasm — 2013: 3.9Malignant Liver Neoplasm — 2014: 4Malignant Liver Neoplasm — 2015: 4Malignant Liver Neoplasm — 2016: 4.2Malignant Liver Neoplasm — 2017: 4.1Malignant Liver Neoplasm — 2018: 4.1Malignant Liver Neoplasm — 2018: 4.1Malignant Liver Neoplasm — 2019: 4Malignant Liver Neoplasm — 2019: 4.1Malignant Liver Neoplasm — 2020: 4.1Malignant Liver Neoplasm — 2020: 4.2Malignant Liver Neoplasm — 2021: 4.3Malignant Liver Neoplasm — 2021: 4.3Malignant Liver Neoplasm — 2022: 4.3Malignant Liver Neoplasm — 2022: 4.2Malignant Liver Neoplasm — 2023: 4.4Malignant Liver Neoplasm — 2023: 4.4Malignant Liver Neoplasm — 2024: 4.4Malignant Liver Neoplasm — 2024: 4.4Leukemia — 1999: 6Leukemia — 2000: 5.9Leukemia — 2001: 5.9Leukemia — 2002: 5.7Leukemia — 2003: 5.6Leukemia — 2004: 5.5Leukemia — 2005: 5.5Leukemia — 2006: 5.5Leukemia — 2007: 5.3Leukemia — 2008: 5.3Leukemia — 2009: 5.3Leukemia — 2010: 5.2Leukemia — 2011: 5.3Leukemia — 2012: 5.1Leukemia — 2013: 5.1Leukemia — 2014: 5Leukemia — 2015: 4.7Leukemia — 2016: 4.9Leukemia — 2017: 4.8Leukemia — 2018: 4.4Leukemia — 2018: 4.5Leukemia — 2019: 4.3Leukemia — 2019: 4.4Leukemia — 2020: 4.3Leukemia — 2020: 4.5Leukemia — 2021: 4.4Leukemia — 2021: 4.4Leukemia — 2022: 4.3Leukemia — 2022: 4.4Leukemia — 2023: 4.1Leukemia — 2023: 4.2Leukemia — 2024: 4.2Leukemia — 2024: 4.1Non-Hodgkin Lymphoma — 1999: 6.9Non-Hodgkin Lymphoma — 2000: 6.7Non-Hodgkin Lymphoma — 2001: 6.4Non-Hodgkin Lymphoma — 2002: 6.2Non-Hodgkin Lymphoma — 2003: 5.9Non-Hodgkin Lymphoma — 2004: 5.7Non-Hodgkin Lymphoma — 2005: 5.6Non-Hodgkin Lymphoma — 2006: 5.4Non-Hodgkin Lymphoma — 2007: 5.3Non-Hodgkin Lymphoma — 2008: 5.1Non-Hodgkin Lymphoma — 2009: 4.9Non-Hodgkin Lymphoma — 2010: 4.9Non-Hodgkin Lymphoma — 2011: 4.7Non-Hodgkin Lymphoma — 2012: 4.7Non-Hodgkin Lymphoma — 2013: 4.5Non-Hodgkin Lymphoma — 2014: 4.5Non-Hodgkin Lymphoma — 2015: 4.3Non-Hodgkin Lymphoma — 2016: 4.3Non-Hodgkin Lymphoma — 2017: 4.1Non-Hodgkin Lymphoma — 2018: 3.8Non-Hodgkin Lymphoma — 2018: 3.8Non-Hodgkin Lymphoma — 2019: 3.9Non-Hodgkin Lymphoma — 2019: 3.9Non-Hodgkin Lymphoma — 2020: 3.8Non-Hodgkin Lymphoma — 2020: 3.7Non-Hodgkin Lymphoma — 2021: 3.7Non-Hodgkin Lymphoma — 2021: 3.8Non-Hodgkin Lymphoma — 2022: 3.6Non-Hodgkin Lymphoma — 2022: 3.6Non-Hodgkin Lymphoma — 2023: 3.5Non-Hodgkin Lymphoma — 2023: 3.5Non-Hodgkin Lymphoma — 2024: 3.4Non-Hodgkin Lymphoma — 2024: 3.4
Malignant Lung Neoplasm24.6 (2024)Malignant Breast Neoplasm18.7 (2024)Malignant Pancreatic Neoplasm10 (2024)Malignant Colon Neoplasm8.2 (2024)Malignant Ovarian Neoplasm5.3 (2024)Malignant Liver Neoplasm4.4 (2024)Leukemia4.1 (2024)Non-Hodgkin Lymphoma3.4 (2024)

cdc-uscsObservedstandard: 2000 U.S. standard population (19 age groups)264 points

Clinical research

Clinical trial activity in United States

Registrant-entered study locations on ClinicalTrials.gov mapped to this country (any study type, any phase). A site is one location; a multi-site study weighs by its number of sites. Recruiting = location status RECRUITING, or the study status when the site has none.

Trial map →
Sites
609,751
Studies with a site here
50,884
Recruiting sites
71,552
Recruiting studies
7,740
Top-level cancers by sites in United States (descendants included)
CancerSitesStudiesRecruiting studiesShare of sites
Malignant Lung Neoplasm83,3974,58273913.7%
Malignant Breast Neoplasm81,6515,55282513.4%
Leukemia51,3984,6596458.4%
Non-Hodgkin Lymphoma46,7474,3346807.7%
Malignant Prostate Neoplasm35,4943,2265425.8%
Malignant Ovarian Neoplasm28,3171,6732574.6%
Malignant Uterine Corpus Neoplasm22,5048381833.7%
Malignant Kidney Neoplasm22,2501,2131693.6%
Malignant Pancreatic Neoplasm20,3701,8123213.3%
Malignant Cervical Neoplasm19,3788301443.2%
Multiple Myeloma18,6421,8792593.1%
Malignant Central Nervous System Neoplasm18,6331,6943023.1%
Malignant Bladder Neoplasm14,6597531502.4%
Malignant Liver Neoplasm12,9021,1871922.1%
Malignant Esophageal Neoplasm11,3686711531.9%
Malignant Gastric Neoplasm10,8317001471.8%
Malignant Colon Neoplasm8,850561621.5%
Malignant Rectal Neoplasm8,089436701.3%
Cutaneous Melanoma7,096165271.2%
Hodgkin Lymphoma5,597647740.9%
Malignant Oropharyngeal Neoplasm4,995297640.8%
Skin Carcinoma4,965232520.8%
Malignant Thyroid Gland Neoplasm4,053301600.7%
Malignant Lip and Oral Cavity Neoplasm4,048228490.7%
Malignant Laryngeal Neoplasm3,712164310.6%
By phase (a Phase II/III study counts in both)
PhaseSitesStudiesRecruiting
Phase 180,06916,1012,353
Phase 2255,71319,5802,684
Phase 3247,9964,036558
Phase 43,751591100

Computed formula ci-trial-sites-v1 · source: clinicaltrials · shares are of sites, not of studies

Data updated 16 hours agoSource updated unknowntrial_site_country_counts

Regulatory

Oncology approval records · US

Records of the country's regulator as ingested (one record = one decision for one application or product identifier). Absence of a record here is not evidence of absence.

All records →

FDA · approved: 2,343 records / 304 drugs

  • Sep 18, 2026Abemaciclib approved cancer not stated in this recordEfficacy supplement 2026-09-18 (see label)openfda
  • Sep 9, 2026Aminolevulinic Acid approved cancer not stated in this recordEfficacy supplement 2026-09-09 (see label)openfda
  • Sep 9, 2026Sevabertinib approved cancer not stated in this recordEfficacy supplement 2026-09-09 (see label)openfda
  • Sep 4, 2026Camizestrant approved Malignant Breast Neoplasmin combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor…openfda
  • Aug 28, 2026Ropeginterferon Alfa-2b approved cancer not stated in this recordEfficacy supplement 2026-08-28 (see label)openfda
  • Aug 25, 2026Zanidatamab approved cancer not stated in this recordEfficacy supplement 2026-08-25 (see label)openfda
  • Aug 25, 2026Tislelizumab approved cancer not stated in this recordEfficacy supplement 2026-08-25 (see label)openfda
  • Jul 24, 2026Enzalutamide approved cancer not stated in this recordEfficacy supplement 2026-07-24 (see label)openfda
  • Jul 24, 2026Enzalutamide approved cancer not stated in this recordEfficacy supplement 2026-07-24 (see label)openfda
  • Jul 14, 2026Selpercatinib approved cancer not stated in this recordEfficacy supplement 2026-07-14 (see label)openfda

Regulatory

Provenance

Sources and freshness

What each source covers for this geography, exactly as ingested. Values are normalized (units, labels) but never changed.

SourceMetricSexYearsCancersEstimate typesStandard populationIngested
cdc-uscsIncidence rate (age-standardized)Both1999–2023 (25)24observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-uscsIncidence rate (age-standardized)Female1999–2023 (25)29observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-uscsIncidence rate (age-standardized)Male1999–2023 (25)27observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-uscsMortality rate (age-standardized)Both1999–2024 (26)23observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-wonderMortality rate (age-standardized)Both2018–2024 (7)36observed2000 U.S. Std. Population2026-09-08
cdc-uscsMortality rate (age-standardized)Female1999–2024 (26)28observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-wonderMortality rate (age-standardized)Female2018–2024 (7)36observed2000 U.S. Std. Population2026-09-08
cdc-uscsMortality rate (age-standardized)Male1999–2024 (26)26observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-wonderMortality rate (age-standardized)Male2018–2024 (7)36observed2000 U.S. Std. Population2026-09-08
cdc-uscsNew casesBoth1999–2023 (25)32observed—2026-09-08
cdc-uscsNew casesFemale1999–2023 (25)29observed—2026-09-08
cdc-uscsNew casesMale1999–2023 (25)27observed—2026-09-08
cdc-uscsDeathsBoth1999–2024 (26)31observed—2026-09-08
cdc-wonderDeathsBoth2018–2024 (7)36observed—2026-09-08
cdc-uscsDeathsFemale1999–2024 (26)28observed—2026-09-08
cdc-wonderDeathsFemale2018–2024 (7)36observed—2026-09-08
cdc-uscsDeathsMale1999–2024 (26)26observed—2026-09-08
cdc-wonderDeathsMale2018–2024 (7)36observed—2026-09-08
cdc-wonderMortality rate (crude)Both2018–2024 (7)36observed—2026-09-08
cdc-wonderMortality rate (crude)Female2018–2024 (7)36observed—2026-09-08
cdc-wonderMortality rate (crude)Male2018–2024 (7)36observed—2026-09-08

Age-standardized rates use the 2000 U.S. standard population (19 age groups); they are not comparable with rates standardized to the World (Segi) population used by IARC. Global comparisons are not available: the IARC Global Cancer Observatory remains under license review and the SEER API awaits credentials (CLAUDE.md §10.3-10.4). Only geographies with licensed observations get a page; see /countries.

Data updated 22 days agoSource updated 1999–202410,680 observations approx. · ranks from snapshots geo=USA